Novo Nordisk CEO Is 'Quite Optimistic' About 2018 Growth

The transcript covers various business aspects of Novo Nordisk, including concerns about patent cliffs and currency risks, the company's optimistic outlook for 2018, and the impact of US tax reforms. It discusses the momentum in the diabetes market, product launches, and the challenges of drug pricing in the US. The conversation also touches on M&A activities, highlighting the company's disciplined approach to acquisitions and partnerships.

What is the main concern for the speaker regarding the US dollar in 2018?

• Depreciation of the US dollar

• Appreciation of the US dollar

• Volatility of the US dollar

• Stability of the US dollar

What is the expected impact of the US tax reform on Novo Nordisk's business?

• Increase in tax rate

• Uncertain impact on tax rate

• Decrease in tax rate

• No change in tax rate

What is the speaker's view on the need for healthcare reform in the US?

• No reform is needed

• Reform is necessary

• Reform is already complete

• Reform is impossible

Why are list prices for diabetes products high according to the speaker?

• Government regulations

• Lack of competition

• High FDA approval costs

• Low production costs

What is the speaker's perspective on market forces affecting insulin pricing?

• Market forces are ineffective

• Market forces are increasing prices

• Market forces are reducing prices

• Market forces have no impact

What was the outcome of Novo Nordisk's bid for Ablynx?

• They partnered with Ablynx

• They withdrew the bid

• They won the bid

• They were outbid by Sanofi

What is Novo Nordisk's strategy for future mergers and acquisitions?

• Acquire as many companies as possible

• Avoid all acquisitions

• Focus on high-value targets

• Stay disciplined with value